Determination of Apixaban Levels in Human Plasma by a High-Throughput Liquid Chromatographic Tandem Mass Spectrometry Assay

被引:10
作者
Tilea, Ioan [1 ]
Popa, Daniela Saveta [2 ]
Xantus, Timea Szakacs [3 ]
Primejdie, Daniela [4 ]
Grigorescu, Bianca [5 ]
Tilea, Brindusa [6 ]
Bocicor, Andreea Elena [1 ]
Varga, Andreea [1 ]
机构
[1] Univ Med & Pharm, Dept Clin Sci Internal Med M3, Family Med, Targu Mures, Romania
[2] Iuliu Hatieganu Univ Med & Pharm, Fac Pharm, Dept Toxicol, Cluj Napoca, Romania
[3] Univ Med & Pharm, Targu Mures, Romania
[4] Iuliu Hatieganu Univ Med & Pharm, Fac Pharm, Dept Clin Pharm, Cluj Napoca, Romania
[5] Univ Med & Pharm, Dept Anesthesiol & Intens Care, Targu Mures, Romania
[6] Univ Med & Pharm, Dept M4, Infect Dis, Targu Mures, Romania
来源
REVISTA ROMANA DE MEDICINA DE LABORATOR | 2015年 / 23卷 / 01期
关键词
apixaban; LC-MS/MS; therapeutic drug monitoring; DIRECT ORAL ANTICOAGULANTS; FACTOR XA INHIBITOR; COAGULATION ASSAYS; PHARMACOKINETICS; SAFETY; PHARMACODYNAMICS; RIVAROXABAN; DABIGATRAN; MANAGEMENT;
D O I
10.1515/rrlm-2015-0006
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
A high-throughput liquid chromatography method with detection by tandem mass spectrometry (LC-MS/MS) was developed and validated for the quantification of apixaban in human plasma. The separation was performed on a Gemini-NX column under isocratic conditions using a 33: 67 (v/v) mixture of acetonitrile and 1 mM ammonium formate in water at 40 degrees C with a flow rate of 0.5 mL/min. The detection of apixaban was performed in multiple reaction monitoring mode (m/z 417.2 from m/z 460.2) with electrospray positive ionization. A single-step protein precipitation with methanol was used for plasma sample preparation. The method was validated with respect to selectivity, linearity (r > 0.994), intra-day and inter-day precision (CV < 14.4 %) and accuracy (bias < 9.5 %) over the range of 9.70 - 970.00 ng/mL plasma. The lower limit of quantification (LLOQ) was 9.70 ng/mL and the recovery was between 97.4 - 104.5 %. The method is fast, efficient, requires the processing of a small volume of plasma (50 mu L), a short run-time (1 min) for chromatographic analysis, and a simple and rapid preparation of samples. It is very well suited for clinical therapeutic drug monitoring and pharmacokinetic studies.
引用
收藏
页码:115 / 125
页数:11
相关论文
共 30 条
[1]   Oral Apixaban for the Treatment of Acute Venous Thromboembolism [J].
Agnelli, Giancarlo ;
Buller, Harry R. ;
Cohen, Alexander ;
Curto, Madelyn ;
Gallus, Alexander S. ;
Johnson, Margot ;
Masiukiewicz, Urszula ;
Pak, Raphael ;
Thompson, John ;
Raskob, Gary E. ;
Weitz, Jeffrey I. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (09) :799-808
[2]  
[Anonymous], EL SUMM PROD CHAR
[3]  
[Anonymous], 2001, FED REG, V66
[4]  
[Anonymous], 2001, CPMPEWPQWP140198 EUR
[5]  
[Anonymous], 2013, GUID IND BIOAN METH
[6]   Safety of new oral anticoagulant drugs: a perspective [J].
Antonio Vilchez, Juan ;
Gallego, Pilar ;
Lip, Gregory Y. H. .
THERAPEUTIC ADVANCES IN DRUG SAFETY, 2014, 5 (01) :8-20
[7]   Pros and cons of new oral anticoagulants [J].
Bauer, Kenneth A. .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, :464-470
[8]  
Brieger D, 2014, AUST FAM PHYSICIAN, V43, P254
[9]   Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions [J].
Cheng, J. W. ;
Barillari, G. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (02) :118-135
[10]   Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [J].
Cui, Yimin ;
Song, Yan ;
Wang, Jessie ;
Yu, Zhigang ;
Schuster, Alan ;
Barrett, Yu Chen ;
Frost, Charles .
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 :177-184